表紙
市場調査レポート

肺扁平上皮癌 - パイプライン製品の分析

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 264094
出版日 ページ情報 英文 157 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
肺扁平上皮癌 - パイプライン製品の分析 Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015
出版日: 2015年08月31日 ページ情報: 英文 157 Pages
概要

肺扁平上皮癌は、非小細胞肺癌の一種です。通常、肺の中央部の気管支(太い気道)から発生する癌です。喫煙が原因とされています。胸痛、喘鳴、不快な呼吸、嗄声、食欲不振、原因不明の体重減少などの症状が見られます。癌のステージによって、化学療法、放射線療法、外科手術などの多くの治療が行われます。

当レポートでは、肺扁平上皮癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

  • 調査範囲

肺扁平上皮癌の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Ascenta Therapeutics, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • エーザイ
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Genentech, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Oncogenex Pharmaceuticals, Inc.
  • 小野薬品工業
  • Vertex Pharmaceuticals Incorporated

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ABT-414
  • apatorsen
  • AT-406
  • AZD-8186
  • BAY-1163877
  • BMS-833923
  • BMS-906024
  • buparlisib hydrochloride
  • FP-1039
  • ipilimumab
  • JNJ-42756493
  • lenvatinib
  • lucitanib
  • lumretuzumab
  • LY-2606368
  • LY-3023414
  • necitumumab
  • nintedanib
  • nivolumab (recombinant)
  • paclitaxel albumin bound
  • pictilisib
  • Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer
  • veliparib
  • VX-970

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6982IDB

Summary

Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015', provides an overview of the Squamous Non-Small Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Squamous Non-Small Cell Lung Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview
    • Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis
  • Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies
  • Squamous Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
  • Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Squamous Non-Small Cell Lung Cancer - Products under Development by Companies
  • Squamous Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes
  • Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Advenchen Laboratories, LLC
    • Ascenta Therapeutics, Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Bayer AG
    • BIND Therapeutics, Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Five Prime Therapeutics, Inc.
    • Genentech, Inc.
    • Incyte Corporation
    • Johnson & Johnson
    • MacroGenics, Inc.
    • Novartis AG
    • Oncogenex Pharmaceuticals, Inc.
    • PsiOxus Therapeutics Limited
    • Vertex Pharmaceuticals Incorporated
  • Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABT-414 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apatorsen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-406 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • atezolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-2014 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-8186 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1163877 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-906024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enadenotucirev - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enoblituzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-1039 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iMDK - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-54828 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-42756493 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lucitanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-3023414 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • necitumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prexasertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • taselisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • veliparib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VX-970 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates
  • Squamous Non-Small Cell Lung Cancer - Dormant Projects
  • Squamous Non-Small Cell Lung Cancer - Discontinued Products
  • Squamous Non-Small Cell Lung Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Aug 24, 2015: Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer
      • Jul 09, 2015: Lilly Statement on FDA Advisory Committee Review of Necitumumab
      • Jun 10, 2015: Survival benefit with 'fully human' EGFR antibody necitumumab in squamous NSCLC
      • May 27, 2015: FDA Advisory Committee To Discuss On Lilly's BLA For necitumumab injection In July 2015
      • May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting
      • Feb 24, 2015: OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
      • Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
      • Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment
      • May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting
      • Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015
  • Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Incyte Corporation, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by MacroGenics, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Dormant Projects, H2 2015
  • Squamous Non-Small Cell Lung Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015
  • Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top